Stop Big Pharma’s $4 Billion Bailout

09-21-2018 Blog Posts

As the country is hoping for lower drug prices, more affordable care, and solutions to the opioid epidemic sweeping the nation, Big Pharma is making backroom deals with Congress to fund a $4 billion bailout.   Using the opioid package as its vehicle, Big Pharma is pushing to lower drug makers’ liability in the doughnut […]

SECOND OPINION: Big Pharma Continues Pointing Fingers for Excessive Drug Prices

09-12-2018 Blog Posts

Apparently, when it comes to out-of-control drug prices, everyone’s to blame but drug makers themselves, who are solely responsible for setting the list prices of the medications we need. Now, Big Pharma is pointing fingers at hospitals, accusing them of price gouging patients – despite the fact that big drug makers have increased the prices […]

Second Opinion: The Real Source of Rising Drug Prices

09-10-2018 Blog Posts

Big Pharma is always eager to play the blame game – attempting to divert attention away from tactics that price-gouge vulnerable patients. But these gratuitous attacks conveniently ignore the facts. To keep Big Pharma and its backers in check, CSRxP is starting a new blog series called “Second Opinion” to set the record straight on […]

CSRxP Statement on Novartis’ $475,000 Price Tag for Kymriah

08-30-2017 Blog PostsPress Release

“While we are very excited about the potential for CAR-T therapies to save lives, Novartis’ pricing decision disappointingly pushes an unsustainable trend even closer to the breaking point.”

CSRxP Calls for Action on CREATES Act

07-27-2017 Blog PostsPress Release

CSRxP Calls for Action on CREATES Act The Campaign for Sustainable Rx Pricing released this statement from spokesman Will Holley on today’s House Judiciary Subcommittee on Regulatory Reform, Commercial and Antitrust Law hearing on Antitrust Concerns and the FDA Approval Process:  “Out-of-control prescription drug prices are an epidemic that harm all Americans. They affect not […]

Avik Roy Unveils “The Competition Prescription”

05-16-2017 Blog PostsPress Release

Read “The Competition Prescription,” a new white paper by Avik Roy, President of Foundation for Research on Equal Opportunity on how federal policy has artificially driven up the cost of prescription drugs, and market-based reforms to bring prices down.

CSRxP Applauds Introduction of the CREATES Act

04-27-2017 Blog PostsPress Release

“Big Pharma’s longstanding pattern of utilizing the REMS process to forestall generic and biosimilar medications from reaching patients is an anticompetitive and cynical abuse of an important tool for patient safety.”

Campaign Continues to Grow with Additional Physician Voices

11-3-2016 Blog PostsPress Release

“The addition of the well-respected Society of General Internal Medicine is crucial as CSRxP continues to build a broad partnership of leaders from every corner of healthcare that are dedicated to fixing the broken prescription drug market,” said CSRxP Executive Director John Rother.

Improving the Prescription Drug Market through Transparency, Competition, and Value

08-3-2016 Blog PostsMediaPress Release

“Patients with chronic conditions, such as Hepatitis C, benefit immensely when breakthrough, life-changing drugs provide a cure where none existed before. But when states are driven to create access limitations to that same drug for their Medicaid populations, we have to acknowledge something is not quite right here.”

CSRxP Statement on Launch of AstraZeneca’s Crestor

07-21-2016 Blog PostsPress Release

“We are glad to see that the court rejected AstraZeneca’s effort to abuse the Orphan Drug Act and restrict generic competitors to Crestor,” said John Rother. “Additional competition in the prescription drug market—including generic options—is crucial to lowering prescription drug prices and providing patients with more affordable choices.”

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.